Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus platinum first-line chemotherapy in mCRPC with DNA damage repair gene abnormalities
ChiCTR2100053482Phase 2Not yet recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Nov 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Huadong Hospital, Fudan University. Primary endpoints: Prostate specific antigen (PSA) response and Bone scan assessment. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
docetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2100053482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053482.